Urology | Specialty

Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

October 14th 2020

Dr. Grivas on the Subgroup Analyses of the JAVELIN Bladder 100 Trial in Advanced Urothelial Cancer

September 24th 2020

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

Long-Term Follow-Up Shows Encouraging OS With Enfortumab Vedotin in Urothelial Carcinoma

September 20th 2020

Long-term follow-up of patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin monotherapy showed encouraging results, with half of patients still alive at 12 months and approximately one-third alive at 18 months.

Immune-Related Biomarkers Linked With OS Benefits of Frontline Maintenance Avelumab in Advanced Urothelial Carcinoma

September 20th 2020

Overall survival benefits of frontline maintenance treatment with avelumab in patients with advanced urothelial cancer were found to be positively associated with biomarkers of immune activity and negativity linked with biomarkers of tumor homeostasis and chronic inflammation.

Improving Survival in Metastatic Urothelial Cancer

August 26th 2020

Physician Extenders in Urology Practices, Part II

August 10th 2012

Maximum 12-Month Follow-Up Suffices in More than Half of Men with Surgically-Treated Invasive Penile Cancer

May 16th 2012

In men with primary squamous cell carcinoma of the penis who have undergone surgery that removed all glanular epithelium a maximum 12-month follow-up period is recommended.

The Importance of Correct Coding in Specialty-Focused Cancer Treatment Centers

May 15th 2012

When you consider how complex the system is, and how little training physicians get in medical school about coding, it stands to reason that practice leadership must emphasize its importance.

A Word of Welcome

May 14th 2012

It is with great pleasure that I welcome you to the inaugural issue of Urologists in Cancer Care.

Battling the Odds in RCC: Interview With Brian Rini, MD

May 5th 2012

An interview with Brian Rini, MD, whose research has focused on RCC, prostate, and other genitourinary cancers, as well as on antiangiogenic therapy and immunotherapy.

x